Table 1 Patient baseline characteristics

From: Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006)

 

Total (n  =  37)

Age, median (range), years

56.5 (33–75)

Sex, n (%)

 Male

35 (94.6)

 Female

2 (5.4)

ECOG performance status score, n (%)

 0

8 (21.6)

 1

29 (78.4)

HBV infection, n (%)

 Positive

35 (94.6)

 Negative

2 (5.4)

Barcelona Clinic Liver Cancer stage at initial diagnosis, n (%)

 B

18 (48.6)

 C

19 (51.4)

China liver cancer staginga, n (%)>

 IIb

18 (48.6)

 IIIa

19 (51.4)

Child-Pugh Classification, n (%)

 A

36 (97.3)

 B7

1 (2.7)

High-risk factors for recurrence, n (%)

 Four or more tumors

18 (48.6)

 Vp1/2 portal vein tumor thrombus

13 (35.1)

 Vv1/2 hepatic vein tumor thrombus

4 (10.8)

 Four or more tumors with Vp1/2 portal vein tumor thrombus

2 (5.4)

  1. aThe China Liver Cancer Staging (CNLC) system recommends classifying HCC patients with stage IIb, which is defined by the presence of four or more tumors, and stage IIIa, which is characterized by blood vessel invasion16.
  2. ECOG Eastern Cooperative Oncology Group, HBV hepatitis B virus.
Back to article page